Prof Xavier Leleu speaks to ecancer at the 2019 International Myeloma Workshop meeting in Boston about the long-term exposure data on KRd
weekly given until progression.
Prof Leleu explains that one of the disadvantages of carfilzomib is that it is administered at the twice a week which is difficult for patients.
He reveals that the ARROW study is comparing the two courses and preliminary data from smaller studies suggests that the activity is the same with once-weekly proving much safer.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.